FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978649917> ?p ?o ?g. }

• W1978649917 endingPage "66" @default.
• W1978649917 startingPage "54" @default.
• W1978649917 abstract "Questions: (1) In female patients with locally advanced breast cancer (labc) and good response to neoadjuvant chemotherapy (nact), including endocrine therapy, what is the role of breast-conserving surgery (bcs) compared with mastectomy? (2) In female patients with labc, a. is radiotherapy (rt) indicated for those who have undergone mastectomy? b. does locoregional rt, compared with breast or chest wall rt alone, result in a higher survival rate and lower recurrence rates? c. is rt indicated for those achieving a pathologic complete response (pcr) to nact? (3) In female patients with labc who receive nact, is the most appropriate axillary staging procedure sentinel lymph node biopsy (slnb) or axillary dissection? Is slnb indicated before nact rather than at the time of surgery? (4) How should female patients with labc that does not respond to initial nact be treated? Methods: This guideline was developed by Cancer Care Ontario’s Program in Evidence-Based Care (pebc) and the Breast Cancer Disease Site Group (dsg). A systematic review was prepared based on literature searches conducted using the medline and embase databases for the period 1996 to December 11, 2013. Guidelines were located from that search and from the Web sites of major guideline organizations. The working group drafted recommendations based on the systemic review. The systematic review and recommendations were then circulated to the Breast Cancer dsg and the pebc Report Approval Panel for internal review; the revised document underwent external review. The full three-part evidence series can be found on the Cancer Care Ontario Web site. Recommendations: a. For most patients with labc, modified radical mastectomy should be considered the standard of care. For some patients with noninflammatory labc, bcs can be considered on a case-by-case basis when the surgeon deems that the disease can be fully resected and the patient expresses a strong preference for breast preservation. b. For patients with labc, rt after mastectomy is recommended. c. It is recommended that, after bcs or mastectomy, patients with labc receive locoregional rt encompassing the breast or chest wall and local node-bearing areas. d. It is recommended that postoperative rt remain the standard of care for patients with labc who achieve pcr to nact. e. It is recommended that axillary dissection remain the standard of care for axillary staging in labc, with the judicious use of slnb in patients who are advised of the limitations of the current data. f. Although slnb either before or after nact is technically feasible, the data are insufficient to make any recommendation about the optimal timing of slnb with respect to nact. Limited data suggest higher sentinel lymph node identification rates and lower false negative identification rates when slnb is conducted before nact; however, those data must be balanced against the requirement for two operations if slnb is not performed at the time of resection of the main tumour. g. It is recommended that patients receiving neoadjuvant anthracycline–taxane-based therapy (or other sequential regimens) whose tumours do not respond to the initial agent or agents, or who experience disease progression, be expedited to the next agent or agents of the regimen. h. For patients who, in the opinion of the treating physician, fail to respond or progress on firstline nact, several therapeutic options can be considered, including second-line chemotherapy, hormonal therapy (if appropriate), rt, or immediate surgery (if technically feasible). Treatment should be individualized through discussion at a multidisciplinary case conference, considering tumour characteristics, patient factors and preferences, and risk of adverse effects. i. It is recommended that prospective randomized clinical trials be designed for patients with labc who fail to respond to nact so that more definitive treatment recommendations can be developed." @default.
• W1978649917 created "2016-06-24" @default.
• W1978649917 creator A5014478470 @default.
• W1978649917 creator A5023572972 @default.
• W1978649917 creator A5030257682 @default.
• W1978649917 creator A5052115098 @default.
• W1978649917 creator A5066991460 @default.
• W1978649917 creator A5082271881 @default.
• W1978649917 date "2015-03-01" @default.
• W1978649917 modified "2023-10-01" @default.
• W1978649917 title "Locoregional Therapy of Locally Advanced Breast Cancer: A Clinical Practice Guideline" @default.
• W1978649917 cites W1760304583 @default.
• W1978649917 cites W1783107099 @default.
• W1978649917 cites W1857442781 @default.
• W1978649917 cites W1956766950 @default.
• W1978649917 cites W1965411781 @default.
• W1978649917 cites W1966064734 @default.
• W1978649917 cites W1967032465 @default.
• W1978649917 cites W1978178465 @default.
• W1978649917 cites W1979470803 @default.
• W1978649917 cites W1985048372 @default.
• W1978649917 cites W1989747842 @default.
• W1978649917 cites W1993173577 @default.
• W1978649917 cites W1998371653 @default.
• W1978649917 cites W2001069453 @default.
• W1978649917 cites W2020861375 @default.
• W1978649917 cites W2066025598 @default.
• W1978649917 cites W2068903161 @default.
• W1978649917 cites W2069430097 @default.
• W1978649917 cites W2070281077 @default.
• W1978649917 cites W2075244132 @default.
• W1978649917 cites W2076099449 @default.
• W1978649917 cites W2087179076 @default.
• W1978649917 cites W2087263485 @default.
• W1978649917 cites W2100025800 @default.
• W1978649917 cites W2103218083 @default.
• W1978649917 cites W2105009450 @default.
• W1978649917 cites W2107073127 @default.
• W1978649917 cites W2113334910 @default.
• W1978649917 cites W2127267391 @default.
• W1978649917 cites W2129825983 @default.
• W1978649917 cites W2131915049 @default.
• W1978649917 cites W2134627157 @default.
• W1978649917 cites W2142059226 @default.
• W1978649917 cites W2143306345 @default.
• W1978649917 cites W2153158488 @default.
• W1978649917 cites W2154346936 @default.
• W1978649917 cites W2157809720 @default.
• W1978649917 cites W2158615473 @default.
• W1978649917 cites W2164774797 @default.
• W1978649917 cites W2172114428 @default.
• W1978649917 cites W2216817786 @default.
• W1978649917 cites W2221006098 @default.
• W1978649917 cites W2287271371 @default.
• W1978649917 cites W2318610219 @default.
• W1978649917 cites W2335018892 @default.
• W1978649917 cites W2415631894 @default.
• W1978649917 cites W364548534 @default.
• W1978649917 doi "https://doi.org/10.3747/co.22.2316" @default.
• W1978649917 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4381791" @default.
• W1978649917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25848339" @default.
• W1978649917 hasPublicationYear "2015" @default.
• W1978649917 type Work @default.
• W1978649917 sameAs 1978649917 @default.
• W1978649917 citedByCount "27" @default.
• W1978649917 countsByYear W19786499172015 @default.
• W1978649917 countsByYear W19786499172016 @default.
• W1978649917 countsByYear W19786499172017 @default.
• W1978649917 countsByYear W19786499172018 @default.
• W1978649917 countsByYear W19786499172019 @default.
• W1978649917 countsByYear W19786499172020 @default.
• W1978649917 countsByYear W19786499172021 @default.
• W1978649917 countsByYear W19786499172022 @default.
• W1978649917 countsByYear W19786499172023 @default.
• W1978649917 crossrefType "journal-article" @default.
• W1978649917 hasAuthorship W1978649917A5014478470 @default.
• W1978649917 hasAuthorship W1978649917A5023572972 @default.
• W1978649917 hasAuthorship W1978649917A5030257682 @default.
• W1978649917 hasAuthorship W1978649917A5052115098 @default.
• W1978649917 hasAuthorship W1978649917A5066991460 @default.
• W1978649917 hasAuthorship W1978649917A5082271881 @default.
• W1978649917 hasBestOaLocation W19786499171 @default.
• W1978649917 hasConcept C121608353 @default.
• W1978649917 hasConcept C126322002 @default.
• W1978649917 hasConcept C141071460 @default.
• W1978649917 hasConcept C142724271 @default.
• W1978649917 hasConcept C143998085 @default.
• W1978649917 hasConcept C17744445 @default.
• W1978649917 hasConcept C199539241 @default.
• W1978649917 hasConcept C2777704003 @default.
• W1978649917 hasConcept C2777757722 @default.
• W1978649917 hasConcept C2779473830 @default.
• W1978649917 hasConcept C2780182762 @default.
• W1978649917 hasConcept C2780212769 @default.
• W1978649917 hasConcept C2781467025 @default.
• W1978649917 hasConcept C509974204 @default.
• W1978649917 hasConcept C530470458 @default.
• W1978649917 hasConcept C61434518 @default.

• next